medigraphic.com
ISSN 2007-2783 (Impreso)
Órgano Oficial del Instituto Científico Pfizer

2011, Número 2

<< Anterior Siguiente >>

Residente 2011; 6 (2)


¿Es posible modelar esquizofrenia en un modelo animal?

Genis AD, Lopéz-Rubacava C

Idioma: Español
Referencias bibliográficas: 51
Paginas: 120-126
Archivo PDF: 63.68 Kb.


RESUMEN

La esquizofrenia es un trastorno mental incapacitante caracterizado por la presencia de ideas delirantes, alucinaciones, desorganización en el lenguaje, alogia y abulia, entre otros. Este trastorno es una de las enfermedades mentales más difíciles de diagnosticar y con una etiología multifactorial, lo que dificulta su tratamiento y estudio. En la actualidad se han desarrollado diversos modelos animales que han ayudado a los investigadores a entender un poco más la enfermedad, a estudiar el mecanismo de acción de los antipsicóticos y a proponer nuevas terapias para su tratamiento. El presente trabajo hace una revisión de algunos de los modelos animales que más se utilizan en la investigación preclínica de la esquizofrenia y analiza sus ventajas y desventajas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Msghina M, Liberg B. [Schizophrenia, neurodegeneration and antipsychotic agents]. Lakartidningen 2009; 106(47): 3183; discussion 3183.

  2. Ardizzone I, Marconi A, Nardecchia F. [Obstetric complications and early-onset schizophrenia: a case-control study]. Riv Psichiatr 2009; 44(2): 117-121.

  3. Gioiosa L, Iannitelli A, Aloe L. Stress, anxiety schizophrenia and neurotrophic factors: the pioneer studies with nerve growth factor. Riv Psichiatr 2009; 44(2): 88-94.

  4. Snowden A. Classification of schizophrenia. Part one: the enduring existence of madness. Br J Nurs 2009; 18(19): 1176-1180.

  5. Canuet L, Ishii R, Iwase M, Ikezawa K, Kurimoto R, Takahashi H, Currais A, Azechi M, Nakahachi T, Hashimoto R, Takeda M. Working memory abnormalities in chronic interictal epileptic psychosis and schizophrenia revealed by magnetoencephalography. Epilepsy Behav. 2010 Jan;17(1):109-19. Epub 2009 Dec 9. PubMed PMID: 20004619.

  6. Khaitovich P, Lockstone HE, Wayland MT, Tsang TM, Jayatilaka SD, Guo AJ, Zhou J, Somel M, Harris LW, Holmes E et al. Metabolic changes in schizophrenia and human brain evolution. Genome Biol 2008; 9(8): R124.

  7. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 2009; 35(3): 549-562.

  8. Sakumoto N, Kondo T, Mihara K, Suzuki A, Yasui-Furukori N. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia. Psychiatry Clin Neurosci 2007; 61(2): 174-180.

  9. Lin CH, Lane HY, Tsai GE. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav. 2011 Apr 1. [Epub ahead of print] PubMed PMID: 21463651.

  10. Guo X, Hamilton PJ, Reish NJ, Sweatt JD, Miller CA, Rumbaugh G. Reduced expression of the NMDA receptor-interacting protein SynGAP causes behavioral abnormalities that model symptoms of Schizophrenia. Neuropsychopharmacology 2009; 34(7): 1659-1672.

  11. Charych EI, Liu F, Moss SJ, Brandon NJ. GABA(A) receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders. Neuropharmacology 2009; 57(5-6): 481-495.

  12. Fatemi SH, Folsom TD, Thuras PD. Deficits in GABA(B) receptor system in schizophrenia and mood disorders: a postmortem study. Schizophr Res. 2011 May;128(1-3):37-43. Epub 2011 Feb 8. PubMed PMID: 21303731; PubMed Central PMCID:PMC3085603.

  13. Adams W, van den Buuse M. Hippocampal serotonin depletion facilitates the enhancement of prepulse inhibition by risperidone: Possible role of 5-HT(2C) receptors in the dorsal hippocampus. Neuropharmacology 61(3):458-467.

  14. Lung FW, Shu BC, Kao WT, Chen CN, Ku YC, Tzeng DS. Association of DRD4 uVNTR and TP53 codon 72 polymorphisms with schizophrenia: a case-control study. BMC Med Genet 2009; 10: 147.

  15. Zakharyan R, Boyajyan A, Arakelyan A, Gevorgyan A, Mrazek F, Petrek M. Functional variants of the genes involved in neurodevelopment and susceptibility to schizophrenia in an Armenian population. Hum Immunol. 2011 May 24. [Epub ahead of print] PubMed PMID: 21641949.

  16. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977; 266(5604): 730-732.

  17. Willner P. Handdook of depression and anxiety. Abiological approach. N.Y.: Maercel Dekker; 1994.

  18. Rideout AL, Carroll JC, Blaine SM, Cremin C, Dorman H, Gibbons CA, Honeywell C, Meschino WS, Permaul J, Allanson J. Genetics: schizophrenia. Can Fam Physician 2009; 55(12): 1207.

  19. Young JW, Zhou X, Geyer MA. Animal models of schizophrenia. Curr Top Behav Neurosci. 2010;4:391-433. Review. PubMed PMID: 21312408.

  20. Rubinstein G. Schizophrenia, infection and temperature. An animal model for investigating their interrelationships. Schizophr Res 1993; 10(2): 95-102.

  21. Lubow RE. Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia. Schizophr Bull 2005; 31(1): 139-153.

  22. Peleg-Raibstein D, Knuesel I, Feldon J. Amphetamine sensitization in rats as an animal model of schizophrenia. Behav Brain Res 2008; 191(2): 190-201.

  23. Govek SP, Bonnefous C, Hutchinson JH, Kamenecka T, McQuiston J, Pracitto R, Zhao LX, Gardner MF, James JK, Daggett LP et al. Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia. Bioorg Med Chem Lett 2005; 15(18): 4068-4072.

  24. Liu F, Zou X, Sadovova N, Zhang X, Shi L, Guo L, Qian F, Wen Z, Patterson TA, Hanig JP, Paule MG, Slikker W Jr, Wang C. Changes in gene expression after phencyclidine administration in developing rats: a potential animal model for schizophrenia. Int J Dev Neurosci. 2011 May;29(3):351-8. Epub 2010 Aug 5. PubMed PMID: 20691775.

  25. Borison RL, Havdala HS, Diamond BI. Chronic phenylethylamine stereotypy in rats: a new animal model for schizophrenia? Life Sci 1977; 21(1): 117-122.

  26. Swerdlow NR, Geyer MA. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacol Biochem Behav 1993; 44(3): 741-744.

  27. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 1990; 47(2): 181-188.

  28. Seillier A, Giuffrida A. Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. Behav Brain Res 2009; 204(2): 410-415.

  29. Willi R, Weinmann O, Winter C, Klein J, Sohr R, Schnell L, Yee BK, Feldon J, Schwab ME. Constitutive genetic deletion of the growth regulator Nogo-A induces schizophrenia-related endophenotypes. J Neurosci 30(2): 556-567.

  30. Pappas GD, Kriho V, Liu WS, Tremolizzo L, Lugli G, Larson J. Immunocytochemical localization of reelin in the olfactory bulb of the heterozygous reeler mouse: an animal model for schizophrenia. Neurol Res 2003; 25(8): 819-830.

  31. Powell SB. Models of neurodevelopmental abnormalities in schizophrenia. Curr Top Behav Neurosci. 2010;4:435-81. Review. PubMed PMID: 21312409.

  32. Lipska BK, Jaskiw GE, Weinberger DR. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 1993; 9(1): 67-75.

  33. Le Pen G, Grottick AJ, Higgins GA, Martin JR, Jenck F, Moreau JL. Spatial and associative learning deficits induced by neonatal excitotoxic hippocampal damage in rats: further evaluation of an animal model of schizophrenia. Behav Pharmacol 2000; 11(3-4): 257-268.

  34. Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 2000; 23(3): 223-239.

  35. Al-Amin HA, Weinberger DR, Lipska BK. Exaggerated MK-801-induced motor hyperactivity in rats with the neonatal lesion of the ventral hippocampus. Behav Pharmacol 2000; 11(3-4): 269-278.

  36. Swerdlow NR, Halim N, Hanlon FM, Platten A, Auerbach PP. Lesion size and amphetamine hyperlocomotion after neonatal ventral hippocampal lesions: more is less. Brain Res Bull 2001; 55(1): 71-77.

  37. Risterucci C, Jeanneau K, Schoppenthau S, Bielser T, Kunnecke B, von Kienlin M, Moreau JL. Functional magnetic resonance imaging reveals similar brain activity changes in two different animal models of schizophrenia. Psychopharmacology (Berl) 2005; 180(4):724-734.

  38. Chambers RA, Moore J, McEvoy JP, Levin ED. Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. Neuropsychopharmacology 1996; 15(6): 587-594.

  39. Lipska BK, Weinberger DR. A neurodevelopmental model of schizophrenia: neonatal disconnection of the hippocampus. Neurotox Res 2002; 4(5-6): 469-475.

  40. Wood GK, Lipska BK, Weinberger DR. Behavioral changes in rats with early ventral hippocampal damage vary with age at damage. Brain Res Dev Brain Res 1997; 101(1-2): 17-25.

  41. Tseng KY, Lewis BL, Lipska BK, O’Donnell P. Post-pubertal disruption of medial prefrontal cortical dopamine-glutamate interactions in a developmental animal model of schizophrenia. Biol Psychiatry 2007; 62(7): 730-738.

  42. Sams-Dodd F, Lipska BK, Weinberger DR. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology (Berl) 1997; 132(3): 303-310.

  43. Becker A, Grecksch G. Haloperidol and clozapine affect social behaviour in rats postnatally lesioned in the ventral hippocampus. Pharmacol Biochem Behav 2003; 76(1): 1-8.

  44. Alquicer G, Silva-Gomez AB, Peralta F, Flores G. Neonatal ventral hippocampus lesion alters the dopamine content in the limbic regions in postpubertal rats. Int J Dev Neurosci 2004; 22(2): 103-111.

  45. Flores G, Barbeau D, Quirion R, Srivastava LK. Decreased binding of dopamine D3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J Neurosci 1996; 16(6): 2020-2026.

  46. Lipska BK, Weinberger DR. Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Brain Res Dev Brain Res 1993; 75(2): 213-222.

  47. Schroeder H, Grecksch G, Becker A, Bogerts B, Hoellt V. Alterations of the dopaminergic and glutamatergic neurotransmission in adult rats with postnatal ibotenic acid hippocampal lesion. Psychopharmacology (Berl) 1999; 145(1): 61-66.

  48. Lillrank SM, Lipska BK, Bachus SE, Wood GK, Weinberger DR. Amphetamine-induced c-fos mRNA expression is altered in rats with neonatal ventral hippocampal damage. Synapse 1996; 23(4): 292-301.

  49. Molteni R, Lipska BK, Weinberger DR, Racagni G, Riva MA. Developmental and stress-related changes of neurotrophic factor gene expression in an animal model of schizophrenia. Mol Psychiatry 2001; 6(3): 285-292.

  50. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev Neurosci 1999; 10(1): 59-90.

  51. Lipska BK, Lerman DN, Khaing ZZ, Weickert CS, Weinberger DR. Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs. Eur J Neurosci 2003; 18(2): 391-402.




2020     |     www.medigraphic.com